RUANDA MEJIA: Open Payments
NPI 1851941504 · CHICAGO, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$796 in 26 payments from 10 companies in 2025. Trend: 2023 $138 · 2024 $859 · 2025 $796
Food & beverage: $796
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 5 | $311 |
| Ardelyx, Inc. | 3 | $141 |
| Janssen Biotech, Inc. | 4 | $79 |
| ABBVIE INC. | 4 | $76 |
| Novo Nordisk Inc | 2 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Gilead Sciences, Inc. | 1 | $34 |
| Phathom Pharmaceuticals, Inc. | 3 | $23 |
| Lilly USA, LLC | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
Products named: REZDIFFRA, IBSRELA, TREMFYA, Wegovy, RINVOQ, ENTYVIO, SKYRIZI, VOQUEZNA.
Industry payments across IL — which companies pay providers there.
